We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metabolic Syndrome in Patients With First-episode Schizophrenia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00957294
First Posted: August 12, 2009
Last Update Posted: January 23, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Aarhus ( Aarhus University Hospital )
August 3, 2009
August 12, 2009
January 23, 2015
August 2009
April 2013   (Final data collection date for primary outcome measure)
metabolic syndrome [ Time Frame: 1 year ]
Same as current
Complete list of historical versions of study NCT00957294 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Metabolic Syndrome in Patients With First-episode Schizophrenia
The Metabolic Syndrome in Patients With First-episode Schizophrenia - Prognosis and Prediction.
The metabolic syndrome (MetS) is highly prevalent in patients with schizophrenia and is a major risk factor of type-2 diabetes, cardiovascular disease and early death. Genetic factors, antipsychotic medication, sleeping disturbances and unhealthy lifestyle are possible causes of developing metabolic syndrome. Several studies have investigated the metabolic side-effects of antipsychotic medication. However it is still unanswered how unhealthy lifestyle, comprising physical inactivity, smoking, unhealthy dieting, and sleeping disturbances adds to the metabolic risk of patients with schizophrenia. The aim of this study is to investigate the prevalence and development of MetS in first-episode patients with schizophrenia and 1 year after onset of treatment. The study's main hypothesis is that physical inactivity, regardless of medication, is an independent risk factor for metabolic syndrome in patients with schizophrenia. In comparison inpatients with major depression and healthy controls, both matched on gender, age and level of education will be included in the study. It is anticipated that the study's results will provide new knowledge about the risk of developing metabolic syndrome in first-episode schizophrenia and how different risk factors contribute to this.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients admitted to The OPUS project, Region of Midtjylland, Denamrk In comparison in-patients with major depression, Aarhus University Hospital, Risskov and healthy controls matched on gender, age and level of education.
  • Metabolic Syndrome X
  • Schizophrenia
Not Provided
  • Schizophrenia
    Patients with first-episode schizophrenia age 18-45 years
  • Depression
    First-time hospitalized patients with depression age 18-45 years
  • healthy controls
    Healthy controls matched on age and gender (18-45 years)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
203
April 2013
April 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with ICD-10 diagnosed schizophrenia

Exclusion Criteria:

  • Antipsychotic medication > 6 weeks before inclusion
  • Physical disability
  • Pregnancy
  • IQ< 55
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00957294
Lene Nyboe Jacobsen
No
Not Provided
Not Provided
University of Aarhus ( Aarhus University Hospital )
Aarhus University Hospital
Not Provided
Not Provided
University of Aarhus
March 2012